The next chapter of radiopharmaceutical therapy starts now

Leading-edge technologies in the fight against cancer

We are a next generation radiopharmaceutical company, taking cancer head on.

For what’s ahead

Precision is the future of cancer care. Radiopharmaceutical products could offer new hope to patients with cancer.

What to expect

Treatments in development

We are pushing forward the next-generation of radiopharmaceuticals with our exciting pipeline.

About our Pipeline

Focused treatment

With focus and precision, our products direct the power of high energy particles towards cancer - and only cancer.

Learn the science

Clinical trials

Learn more about our ongoing study for Men with Metastatic Castration-Resistant Prostate Cancer. Now enrolling in phase 3.

Splash trial

News + Stories

Press Release
4 Jan
2022

POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development

Dr. Vincent brings more than 25 years of pharma business development experience along with deep technical expertise including drug development relating to oncology/immuno-oncology, inflammatory, and autoimmune disease

Press Release
1 Dec
2021

POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes

Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join as VP Medical Affairs, and Michael Gottlieb (CCO) to depart the Company to pursue other opportunities. Jonathan Ross Goodman elected Lead Independent Director of the Board of Directors.